Analysts’ Top Healthcare Picks: Axsome Therapeutics (AXSM), Abbott Laboratories (ABT)
TipRanks (Wed, 19-Feb 5:10 AM ET)
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Benzinga (Fri, 14-Feb 3:04 PM ET)
Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care
PRNewswire (Tue, 4-Feb 11:27 AM ET)
Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
PRNewswire (Wed, 22-Jan 7:00 AM ET)
PRNewswire (Tue, 14-Jan 11:01 AM ET)
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
Business Wire (Mon, 6-Jan 9:00 AM ET)
Abbott Hosts Conference Call for Fourth-Quarter Earnings
PRNewswire (Thu, 2-Jan 9:00 AM ET)
PRNewswire (Tue, 17-Dec 7:00 AM ET)
Abbott Increases Quarterly Dividend for 53rd Consecutive Year
PRNewswire (Fri, 13-Dec 10:58 AM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of February 19, 2025, ABT stock price climbed to $132.13 with 3,500,146 million shares trading.
ABT has a beta of 0.16, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.01 to the broad based SPY ETF.
ABT has a market cap of $229.17 billion. This is considered a Mega Cap stock.
Last quarter Abbott Laboratories reported $11 billion in Revenue and $1.34 earnings per share. This fell short of revenue expectation by $-56 million and met earnings estimates .
In the last 3 years, ABT traded as high as $132.65 and as low as $89.67.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
ABT has underperformed the market in the last year with a return of +17.9%, while SPY returned +24.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ABT shares. However, ABT has outperformed the market in the last 3 month and 2 week periods, returning +13.1% and +2.3%, while SPY returned +4.5% and +1.9%, respectively. This indicates ABT has been having a stronger performance recently.
ABT support price is $128.20 and resistance is $132.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.